How long before chasteberry helps my PMS?

Some improvement often appears by the second cycle, with the fuller effect at three cycles. Trials measured outcomes over three consecutive cycles.

Which symptoms respond best?

Breast tenderness and irritability respond most consistently, followed by mood change, bloating and headache.

Should I only take it in the second half of my cycle?

No. Trials dosed continuously through the whole cycle, including menstruation, and that is what the results are based on.

Is it safe with the pill?

There is a theoretical interaction with hormonal contraception, so raise it with your clinician before combining them.

Can I take it while trying to conceive?

Discuss it with a clinician first, and stop if you conceive. It is not recommended in pregnancy or during fertility treatment cycles.

Is it the same as taking a hormone?

No. It acts on dopamine receptors in the pituitary and lowers prolactin rather than supplying oestrogen or progesterone.

Condition

Strong Evidence

Effectiveness 3/5

Vitex (Chasteberry) for Premenstrual Syndrome (PMS)

Vitex agnus-castus is among the better-supported herbal options for premenstrual syndrome, particularly breast tenderness and irritability.

Overview

Chasteberry is the best-evidenced herbal option for premenstrual syndrome. Randomised placebo-controlled trials, including a widely cited BMJ study, and two meta-analyses report meaningful reductions in the cluster that bothers people most: breast tenderness, irritability, low mood, bloating and headache. Effects are usually partial rather than complete, and they build across cycles rather than within days. It suits cyclical symptoms tied to the luteal phase, particularly where breast tenderness is prominent. It is not a treatment for premenstrual dysphoric disorder, where symptoms disable work or relationships and SSRIs have far stronger evidence, and it is not appropriate in pregnancy.

Verdict

Likely effective

Two meta-analyses of double-blind randomised trials and several individual placebo-controlled trials show Vitex agnus-castus extract reduces overall PMS symptom scores, with the clearest effect on breast tenderness and irritability.

How It Works

Chasteberry does not act like a hormone. Its diterpenes bind dopamine D2 receptors in the pituitary, and dopamine agonism there suppresses prolactin release. Because mildly raised prolactin contributes to breast tenderness and can disturb the luteal phase, lowering it plausibly explains why breast symptoms respond most consistently. Two further actions are proposed. Flavonoids such as apigenin have weak oestrogen receptor beta activity, and some constituents bind mu-opioid receptors, which may account for mood and irritability effects. The receptor-level, pituitary-mediated route also explains the slow onset: the hypothalamic-pituitary-ovarian axis adjusts across cycles, not days, which is why trials measured outcomes at three cycles.

Pathways involved

Dopamine D2 receptor agonism in the pituitary

Prolactin suppression

Luteal phase regulation

Oestrogen receptor beta binding (weak)

Mu-opioid receptor activity

Dosing & Protocol

The trial standard is a standardised extract at roughly 20 to 40 mg of extract daily, commonly sold as 400 mg of standardised preparation, taken once each morning. Named extracts with trial support include BNO 1095 and Ze 440. Doses were given continuously through the whole cycle rather than only in the luteal phase, which is how the benefit accumulated. Expect partial improvement by the second cycle and the fuller effect at three. Since dried berry powders and tinctures vary considerably in diterpene content, a standardised extract matching a trialled preparation is the sensible choice. If nothing has changed after three full cycles, further continuation is unlikely to help.

Scenario	Dose	Form	Timing
General PMS symptoms	400 mg standardised extract daily	Standardised Vitex agnus-castus extract	Morning, with food
Trial-matched extract	20-40 mg extract daily (BNO 1095 or Ze 440)	Standardised extract	Once daily, continuously
Predominant breast tenderness	400 mg daily	Standardised extract	Morning, through the whole cycle
Trial duration	3 consecutive cycles before judging	Any standardised extract	Continuous, not luteal-phase only

1
Track symptoms for one cycle first· Cycle 0
A daily symptom diary confirms the pattern is genuinely premenstrual and gives you a baseline to judge change against.
2
Check it is appropriate· Before starting
Rule out pregnancy, and review any hormonal contraception, dopamine-acting medication or hormone-sensitive condition with a clinician first.
3
Take 400 mg each morning· Cycles 1-3
Dose continuously through the whole cycle, including menstruation. Luteal-only dosing was not what the trials used.
4
Reassess at cycle 2· Cycle 2
Partial improvement in breast tenderness and irritability by the second cycle is the usual early signal.
5
Decide at cycle 3· Cycle 3
Full benefit appears by three cycles. If the diary shows no change, stop and consider other options.

Evidence

The BMJ randomised, placebo-controlled trial is the anchor: 20 mg daily of extract over three cycles reduced irritability, mood change, anger, headache and breast fullness significantly more than placebo, with more than half of participants classed as responders. A subsequent randomised trial of BNO 1095 in Chinese women with moderate to severe PMS and a further trial in Acta Medica Iranica reproduced the direction and size of that effect. Two meta-analyses of double-blind randomised trials, in the American Journal of Obstetrics and Gynecology and in Complementary Therapies in Medicine, concluded that chasteberry preparations reduce PMS symptoms compared with placebo, while both flagged variable extract standardisation and modest trial sizes as limits on confidence. The consistent picture is a real, moderate, partial benefit rather than symptom elimination.

Best available evidence: Two meta-analyses of double-blind randomised trials plus three placebo-controlled trials
Typical effect: Moderate reduction in overall PMS score; breast tenderness and irritability respond most
Studied dose: 20-40 mg standardised extract daily
Time to effect: Some effect by cycle 2; full benefit at 3 cycles
Certainty of evidence: Strong for PMS overall; limited by variable extract standardisation between products

Two meta-analyses of double-blind randomised trials of Vitex agnus-castus in PMS, alongside three placebo-controlled or comparative randomised trials including the BMJ study.

The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis

Score: 9/10

2017

meta_analysis

n=1071

Verkaik S, Kamperman AM, van Westrhenen R +1 more

Trials with low risk of bias yielded substantially smaller effect sizes than weaker studies of Vitex agnus castus.

View source

Vitex agnus-castus in premenstrual syndrome: a meta-analysis of double-blind randomised controlled trials

Score: 8/10

2019

meta_analysis

Csupor D, Lantos T, Hegyi P +6 more

Vitex was more effective than placebo, though most trials had methodological shortcomings and low certainty.

View source

Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women

Score: 7/10

2010

rct

n=217

Ma L, Lin S, Chen R +3 more

Premenstrual syndrome diary scores fell significantly more with Vitex than placebo across three cycles.

View source

Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study

Score: 8/10

2001

rct

n=178

Schellenberg R

Responder rate was 52% with agnus castus versus 24% with placebo in women with premenstrual syndrome.

View source

Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome

Score: 6/10

2012

rct

n=128

Zamani M, Neghab N, Torabian S

Symptom improvement occurred in 62% of the Vitex group versus 24% of the placebo group.

View source

Safety

Reported side effects in trials were mild and uncommon: nausea, headache, gastrointestinal upset, acne, and occasionally cycle changes or spotting. Withdrawal rates were low and comparable to placebo, and no serious adverse events were attributed to the extract. The contraindications matter more than the side effects. Chasteberry acts on prolactin and dopamine, so it should not be used in pregnancy or breastfeeding, where safety is unestablished and milk supply may be reduced. Avoid it in hormone-sensitive cancers including breast cancer, and in anyone with a prolactinoma, without specialist advice. Stop if you conceive.

When PMS is something more

Symptoms that disable work or relationships, or any suicidal thought in the luteal phase, may indicate premenstrual dysphoric disorder. That needs medical assessment; SSRIs have much stronger evidence there than any herbal option.

Interactions & Conflicts

Interacts with	Severity	Mechanism	Action
Dopamine agonists (bromocriptine, cabergoline, ropinirole)	high	Additive dopaminergic activity on prolactin regulation	Avoid the combination
Antipsychotics and metoclopramide	high	Chasteberry may oppose dopamine antagonist activity	Avoid without specialist advice
Hormonal contraceptives	moderate	Possible alteration of contraceptive effect via hormonal signalling	Discuss with a clinician; do not rely on it as a reason to change contraception
Hormone replacement therapy	moderate	Potential interference with hormone therapy effects	Use only under medical guidance
In vitro fertilisation and fertility treatment	high	Prolactin and luteal phase effects may disturb controlled protocols	Avoid during treatment cycles
Pregnancy and breastfeeding	high	Unestablished safety; possible reduction in milk supply	Do not use; stop if you conceive

References

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.